Psychologists Petition for New Psychedelic Science Division within APA
Researchers seek to establish an official APA division dedicated to psychedelic science and practice.
1Formalizing Psychedelic Research
A group of psychologists launched a petition in October 2026 to establish a Division of Psychedelic Science and Practice within the American Psychological Association. If successful, this would become the organization's 55th active division. The initiative aims to provide an official home for the rapidly growing field of psychedelic-assisted mental health treatment.
2Rigorous Approval Process
Establishing a new division requires signatures from at least 1% of APA members and a two-thirds vote from the Council of Representatives. Approval is not guaranteed, as the Council previously rejected a technology-focused division in 2014. The group must also complete a candidacy period before receiving final, permanent status within the association.
3Beyond Pharmacological Frameworks
Petitioners argue that psychedelic care requires a specialized focus beyond existing psychopharmacology models. The proposed division intends to examine altered states of consciousness, therapeutic mechanisms of change, and integration processes. It seeks to act as interdisciplinary connective tissue, bridging basic science with actionable frameworks for clinicians across thirteen different APA divisions.
4Regulatory and Clinical Context
The push occurs despite significant regulatory hurdles, including the FDA's 2024 rejection of MDMA-assisted therapy for PTSD. However, federal activity remains active in 2026, with new clinical trial guidance issued and priority review vouchers granted. The proposed division would offer a venue to discuss these complex regulatory, ethical, and clinical safety questions.
5Expert Steering Committee
The ten-member steering committee includes prominent experts like Matthew W. Johnson, who led pioneering psilocybin trials at Johns Hopkins. Other members bring diverse experience from military mental health, addiction treatment, and academic research. Several members hold professional ties to the psychedelic therapy sector, ensuring deep industry knowledge guides the proposed division's mission.
6Focus on Clinical Competency
The division would support continuing education and develop emerging clinical competency frameworks for patient selection and preparation. It aims to foster discussions on harm reduction for non-prescribing clinicians whose patients use psychedelics outside of clinical settings. These resources would provide essential guidance for practitioners navigating the evolving landscape of psychedelic-assisted therapy.
7Scope and Limitations
In accordance with APA bylaws, the group would operate as a scholarly community rather than a credentialing body. It will not grant clinical licenses, certifications, or prescribing authority. Any educational materials or consensus recommendations produced by the division would remain separate from official APA policy, maintaining its role as a professional forum.
8Translational Research Bridge
Organizers emphasize that the division will serve as a translational bridge between basic science and clinical practice. By focusing on the psychological factors that mediate outcomes, the group hopes to translate research findings into safe, equitable care. This approach addresses the specific needs of patients undergoing treatment for depression and trauma.
9Future of Psychological Inquiry
The petition characterizes psychedelic science as an enduring area of inquiry rather than a temporary niche. By integrating cultural, ethical, and psychological dimensions, the division aims to standardize best practices. Its establishment would mark a significant shift in how the nation's largest psychological organization addresses the therapeutic potential of psychoactive compounds.
Original article: PsyPost — Psychologists Petition for New Psychedelic Science Division within APA